Recombinant anti-interleukin-9 antibodies
US7371383B2 · kind B2 · utility
16Cited by
66References
44Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 11, 2003 |
| Grant date | May 13, 2008 |
| Priority date | — |
| Expiry date | Apr 11, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.